| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
401,347 | 430,909 | 391,481 | 361,375 | 337,366 |
|
Cost of Revenue
|
-72,597 | -79,416 | -70,566 | -61,846 | -65,948 |
|
Gross Profit
|
328,750 | 351,493 | 320,915 | 299,529 | 271,418 |
| Selling, General and Administrative Expenses
|
-238,001 | -262,006 | -246,492 | -223,918 | -225,760 |
|
Research and Development Expenses
|
-72,633 | -90,664 | -90,241 | -90,720 | -92,563 |
|
Operating Income/Expenses
|
-310,634 | -352,670 | -336,733 | -314,638 | -318,323 |
|
Total Operating Profit/Loss
|
18,116 | -1,177 | -15,818 | -15,109 | -46,905 |
| Total Net Finance Income/Expense
|
10,900 | 25,004 | 28,565 | 20,427 | 3,358 |
| Net Investment Income
|
-1,161 | -1,161 | -859 | -264 | 266 |
| Irregular Income/Expenses
|
750 | 750 | 0 | 0 | -27,629 |
|
Non-Operating Income/Expenses, Total
|
10,489 | 24,593 | 27,706 | 20,163 | -24,005 |
|
Pretax Income
|
28,605 | 23,416 | 11,888 | 5,054 | -70,910 |
|
Provision for Income Tax
|
-2,843 | -2,433 | 6,358 | -1,373 | -577 |
|
Net Income from Continuing Operations
|
25,762 | 20,983 | 18,246 | 3,681 | -71,487 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
25,762 | 20,983 | 18,246 | 3,681 | -71,487 |
|
Net Income after Non-Controlling/Minority Interests
|
25,762 | 20,983 | 18,246 | 3,681 | -71,487 |
|
Net Income Available to Common Stockholders
|
25,762 | 20,983 | 18,246 | 3,681 | -71,487 |
|
Diluted Net Income Available to Common Stockholders
|
25,762 | 20,983 | 18,246 | 3,681 | -71,487 |
| Basic EPS
|
0.71 | 0.58 | 0.49 | 0.10 | -1.94 |
| Diluted EPS
|
0.70 | 0.56 | 0.48 | 0.09 | -1.94 |
|
Basic Weighted Average Shares Outstanding
|
36,303.67 | 36,281.88 | 36,984.76 | 38,066.20 | 36,856.14 |
|
Diluted Weighted Average Shares Outstanding
|
36,766.21 | 37,174.76 | 37,840.15 | 39,151.05 | 36,856.14 |
|
Reported Normalized Basic EPS
|
3.18 | 3.17 | 2.57 | 2.11 | 0.23 |
|
Reported Normalized Diluted EPS
|
2.96 | 2.95 | 2.38 | 1.95 | 0.21 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
17,423 | -1,870 | -16,815 | -15,558 | -74,864 |
|
EBITDA
|
30,961 | 12,822 | -6,339 | -9,571 | -64,679 |
|
Normalized EBITDA
|
63,801 | 91,586 | 74,231 | 59,217 | 7,261.43 |
|
Normalized Income
|
55,338.10 | 115,098 | 95,099 | 80,417 | 8,579.50 |
|
Total Unusual Items
|
32,840 | 52,648 | 74,168 | 68,980 | 99,389 |
12/31/2022 - 6/14/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade